GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sunshine Lake Pharma Co 6887.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

38.82

+0.05%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Sunshine Lake Pharma Co

Its shares trade on HKEX under the ticker 6887.HK. It has been listed since 7 August 2025. In the fiscal year to 31 December 2025, it reported revenue of CN¥4.82bn and net income of CN¥272.4m. At that date it held total assets of CN¥11.99bn and shareholders' equity of CN¥4.34bn.

Sunshine Lake Pharma Co., Ltd. operates as a pharmaceutical company. The company is headquartered in Dongguan, Guangdong. The company went IPO on 2025-08-07. The firm focuses on innovative drugs and is also involved in modified new drugs, generic drugs and biosimilars. The Company’s anti-infective products include Kewei (oseltamivir phosphate), for the treatment of influenza (in particular, Type A and Type B influenza viruses), Dongweien (emitasvir phosphate), for the treatment of hepatitis C, and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin and Moxifloxacin Hydrochloride. The Company’s commercialized chronic disease treatment drugs primarily focus on the treatment of diabetes, hyperuricemia, hypertension and stomach acid related disease, including insulin products and generic drugs. The firm also focuses on therapeutic area of oncology.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
7 Aug 2025
Employees
6,550

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company employs 6,550 full-time staff members.
  • It focuses on innovative drugs and biosimilars.
  • It has commercialized chronic disease treatment drugs.

Weaknesses

  • The IPO occurred recently on 2025-08-07.
  • The source description is treated as untrusted facts.
  • The website is https://www.hecpharm.com/.

Opportunities

  • The firm is involved in modified new drugs.
  • It produces generic drugs for infections.
  • It focuses on the therapeutic area of oncology.

Threats

  • The company is headquartered in Dongguan, Guangdong.
  • It operates in the Health Care sector.
  • The ticker is 6887.HK with ISIN CNE1000070M8.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.